Terms: = Thyroid cancer AND HER1, YOR227W AND Prognosis
5 results:
1. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract] [Full Text] [Related]
3. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races.
Kurebayashi J; Moriya T; Ishida T; Hirakawa H; Kurosumi M; Akiyama F; Kinoshita T; Takei H; Takahashi K; Ikeda M; Nakashima K
Breast; 2007 Dec; 16 Suppl 2():S72-7. PubMed ID: 17714947
[TBL] [Abstract] [Full Text] [Related]
4. Inhibition of her1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer.
Kurebayashi J; Okubo S; Yamamoto Y; Sonoo H
Breast Cancer; 2004; 11(1):38-41. PubMed ID: 14718791
[TBL] [Abstract] [Full Text] [Related]
5. Biological and clinical significance of HER2 overexpression in breast cancer.
Kurebayashi J
Breast Cancer; 2001; 8(1):45-51. PubMed ID: 11180765
[TBL] [Abstract] [Full Text] [Related]
